tbuckley/cabot-search huggingface dataset:
A randomized phase III study of cisplatin with or without raltitrexed in patients (pts) with malignant pleural mesothelioma (MPM): an intergroup study of the EORTC Lung Cancer Group and NCIC
Authors: J. P. Van Meerbeeck, C. Manegold, R. Gaafar, R. J. van Klaveren, E. A. Van Marck, M. Vincent, C. Legrand, C. Debruyne, G. Giaccone
Journal: Journal of Clinical Oncology (2004)

7021 Background: MPM is characterized by an increasing incidence and refractoriness to available cytostatic drugs. Phase I and II trials in mesothelioma pts using raltitrexed- a thymidine synthase inhibitor- with and without platinum showed an ORR of 20–35% (Fizazi, 2000 and 2003) and of 21%(Baas, 2003) respectively and provide the rationale for the design of this randomized study. Methods: Eligible pts had to have histologically proven unresectable MPM, not pretreated with chemotherapy, WHO PS ≤ 2, and adequate hematological, renal and hepatic function. Stratification was by institution, PS (0 vs.1–2) and WBC (< 8.3 109/l vs. ≥ 8.3 109/l). After written informed consent, pts were randomized between cisplatin 80 mg/m2 iv on day 1, without (Arm A) or with (Arm B) preceding infusion of raltitrexed 3 mg/m2. Treatment was continued q3 weeks unless refusal, progression or unacceptable toxicity occurred. Appropriate dose reductions were made in case of toxicity. In pts with measurable disease, response was monitored using RECIST criteria. The study was powered to detect a 50% increase in median survival with a 2 sided alpha error of 0.05 and a beta error of 0.2 (sample size of 240 pts). Results: Between November 1999 and January 2003, 250 pts with following characteristics were randomized: 20% females, median age 58 years (range 19–80), PS 0/1/2: 25/62/13% and histological subtype epithelial/non-epithelial: 68/24%.The median number of cycles in arm A was 4 (range 1–9) and in B 5 (range 1–9). Comparable relative dose intensities of cisplatin were obtained. There were no toxic deaths. The main gr ¾ toxicities observed were (in % of pts of arm A/B respectively): neutropenia 8/16, TRC-penia 0/2, fatigue 5/12, nausea 10/14, emesis 7/13, pleuritic pain 10/6, dyspnea 8/10. Among 207 pts with measurable disease, 14 PR in arm A, 1 CR and 24 PR in arm B were observed (ORR 14 vs 23% respectively). Presently, all of the 195 events required for intention to treat analysis have occurred. Median overall and 1 year survival in arm A and B are 8.8 months (95%CI: 7.7–11.4) vs 11.2 months (95%CI: 10.0–13.9) and 40 vs 45% respectively (p= 0.06). Conclusion: the present study shows a trend toward improved survival with a combination of raltitrexed and cisplatin as compared to cisplatin alone in pts with MPM, although this does not reach statistical significance. No significant financial relationships to disclose.
Dose-Dense Weekly Rituximab and Standard CHOP Therapy in 123 Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma; Ganken Ariake Lymphoma Study Group Analysis.
Authors: Masahiro Yokoyama, Yasuhito Terui, Kengo Takeuchi, Hiroaki Asai, Makoto Kodaira, Kyoko Ueda, Shuhei Yamada, Yuko Mishima, Sakura Sakajiri, Takashi Saotome, Shunji Takahashi, Kiyohiko Hatake
Journal: Blood (2009)
PERI-PROCEDURAL USE OF NOVEL ORAL ANTICOAGULATION AGENTS DURING CARDIAC DEVICE IMPLANTATION: ARE THEY SAFE?
Authors: Valay Parikh, Madhav Lavu, Venkat Lakshmi Kishan Vuddanda, Mohammad Jazayeri, Vidhya Reddy, Bhavya Yarlagadda, Himabindu Korra, Rakesh Venkata, Sudharani Bommana, Donita Atkins, Madhu Reddy, Dhanunjaya Lakkireddy
Journal: Journal of the American College of Cardiology (2017)
DOES PATIENT PROSTHESIS MISMATCH DEFINED BY CT LVOT AREA PREDICT DOWNSTREAM CLINICAL OUTCOMES?
Authors: John Mooney, Philipp Blanke, Stephanie Sellers, Danny Dvir, Neil Weissman, Susheel Kodali, Vinod Thourani, Hasan Jilaihawi, Omar Khalique, Rebecca Hahn, Craig Smith, Pamela S. Douglas, John Webb, Grover Rominder, Shaw-Hua Kueh, Mickael Ohana, Chris Naoum, Philippe Pibarot, Aaron Crowley, Wael Jaber, Maria Alu, Rupa Caprihan, Michael Mack, Martin Leon, Jonathon Leipsic
Journal: Journal of the American College of Cardiology (2017)
Poorer survival in males with early breast cancer: Worse prognosis or undertreatment?
Authors: David Odhiambo Okonji, David James Porter
Journal: Journal of Clinical Oncology (2015)

e11521 Background: Male breast cancer (BC) is rare and not extensively studied as males are excluded from most clinical trials. By extrapolation from early female BC, the standard of care for early male BC is mastectomy and adjuvant tamoxifen ± chemotherapy for ER+ disease. Our objective was to investigate early male BC treatment and survival over a 14-year period in Auckland, New Zealand. Methods: 73 M and 11,429 F with BC diagnosed between 2000 and 2013 were identified from the Auckland Breast Cancer Registry. Pts with DCIS (11 M; 1,721 F) and incomplete data (5 M; 407 F) were excluded from analysis. 5 males (6.9%), 407 females (3.6%) had metastatic disease at presentation. Survival outcomes and treatment patterns for males with early BC were compared to females in general and female controls matched for age, tumour size, histologic subtype, grade, N stage, peritumoral vascular invasion (PVi), PR, ER, and HER2 status. Results: Median age at diagnosis was 69.5 and 57.0 yrs in males vs females. 5yr OS was 75% in males vs 85% in all females (HR 1.80; 95% CI 1.08-4.65 P = 0.03) with median follow up of 3.3 yrs. 50% males and 59% females had N0 disease (P = 0.19). N stage (P = 0.04) and grade (P = 0.03) were associated with poorer survival in males. 5yr OS was similar in males and matched females (75% vs 72%) [HR 0.79; 95% CI 0.37-1.65; P = 0.53]. 96% males and 78% females had ER+ disease (P = 0.0014). All endocrine therapy in males was with tamoxifen. Conclusions: Males with BC are more likely than females to present with metastatic disease, and survival of males with early BC is worse than in females. However, treatment patterns were comparable in both sexes and survival in males was similar to matched female controls. This suggests that males have more adverse prognostic factors than females at diagnosis, rather than tumours with different biological behaviour or under-treatment. Treatment Males Females X2 P value n % n % Mastectomy Complete 47 90% 4,787 53% < 0.0001 Partial 4 7.7% 4,103 45% < 0.0001 Radiotherapy 19 37% 5,641 62% 0.0002 Systemic therapy Chemotherapy alone - - 1,288 14% - Chemo/Endocrine 10 19% 1,841 20% 0.86 Endocrine 23 44% 3,254 36% 0.20 None/Declined 19 37% 2,736 30% 0.31
Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study
Authors: Hillard Kaplan, Randall C Thompson, Benjamin C Trumble, L Samuel Wann, Adel H Allam, Bret Beheim, Bruno Frohlich, M Linda Sutherland, James D Sutherland, Jonathan Stieglitz, Daniel Eid Rodriguez, David E Michalik, Chris J Rowan, Guido P Lombardi, Ram Bedi, Angela R Garcia, James K Min, Jagat Narula, Caleb E Finch, Michael Gurven, Gregory S Thomas
Journal: The Lancet (2017)
Abstract P5-16-18: The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer
Authors: MB Brennan, D Wang, P Gass, A Hein, MW Beckmann, PA Fasching
Journal: Cancer Research (2017)

Abstract Pathological complete response (pCR) has been shown to demonstrate improved outcomes in breast cancer. Often novel treatments, such as taxanes or HER2 based therapies, trastuzumab or pertuzumab, have shown an increase of pCR with possible impact on the prognosis of breast cancer patients. These therapies are usually introduced into the patient population through clinical trials. Therefore, it can be hypothesized participation in neoadjuvant clinical trials might improve the pCR rate in early breast cancer patients. The aim of this study was to explore this association. Methods: This is a retrospective study of consecutive breast cancer patients who were treated with a neoadjuvant chemotherapy at a single institution. Trial participation status was known for all patients. From 1995 to 2012 the institution participated in 10 different neoadjuvant chemotherapy trials. Outside those clinical trials, patients were treated according to national neoadjuvant therapy guidelines. Patients who took part in clinical trials were compared with patients who did not take part in clinical trials with appropriate univariate tests. Additionally, logistic regression was performed with pCR as the dependent variable and commonly known predictors of pCR (tumor size and molecular subtype) as independent variables. The model was adjusted for age at diagnosis, year of treatment and trial participation status. Furthermore, exploratory survival analyses were performed. Results: A total of 281 patients were treated within a neoadjuvant clinical trial and 822 patients outside a clinical trial. There are significant differences in the patient populations with regards to age (p=0.0009) and tumor size (&amp;lt;0.0001). pCR rate in patients with trial participation was 21.4% and 19.0% in patients who did not take part in clinical trials. Multivariate logistic regression showed an OR of 1.393 (95%CI 0.937-2.071, p=0.1012). Exploratory survival analyses showed a better prognosis in patients taking part in clinical trials. Conclusions: This study shows an increased chance of pCR in patients taking part in clinical trials; however the statistical test could not show statistical significance. Most likely the effect can be explained by trial participants having access to drugs which improved pCR rates, such as HER2 based therapies or taxanes. Citation Format: Brennan MB, Wang D, Gass P, Hein A, Beckmann MW, Fasching PA. The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-18.
ELOQUENT-1: A phase III, randomized, open-label trial of lenalidomide/dexamethasone with or without elotuzumab in subjects with previously untreated multiple myeloma (CA204-006).
Authors: Meletios A. Dimopoulos, Thierry Facon, Paul Gerard Guy Richardson, Robert Z. Orlowski, Jesùs F. San-Miguel, Sagar Lonial, Kenneth Carl Anderson, Philippe Moreau, Donna Ellen Reece, Anil Singhal, Ronald L. Shazer, Justin Kopit, Antonio Pierangelo Palumbo
Journal: Journal of Clinical Oncology (2012)

TPS8113 Background: Elotuzumab (Elo) is a humanized monoclonal IgG1 antibody targeting the cell surface glycoprotein CS1, which is highly expressed on &gt;95% of MM cells. In a MM xenograft mouse model, the combination of Elo + lenalidomide (Len) significantly reduced tumor volume in a synergistic manner compared with either agent alone. In a phase 2 study (N=73) of Elo (10 or 20 mg/kg) in combination with Len and low-dose-dexamethasone (Dex) in pts with RR MM, the 10 mg/kg dose group (n=36) demonstrated objective response rates (ORR) of 92% in all pts, and 100% in pts who had received only 1 prior therapy (n=16). The higher response rate in pts with fewer prior lines of therapy provides a rationale for investigating this combination earlier in the disease course. This randomized, open-label, phase 3 trial will determine if the addition of Elo to Len/Dex improves progression-free survival (PFS) in pts with newly diagnosed, untreated MM. Methods: Pts (N=750) with newly diagnosed symptomatic MM ineligible for stem cell transplant will be randomized in a 1:1 ratio to receive 28-day cycles of Len 25 mg PO (days1-21) and Dex 40 mg PO (days 1, 8, 15 and 22) with or without Elo. Elo dose and schedule is 10 mg/kg IV on days 1, 8, 15, 22 in the first 2 cycles and on days 1 and 15 of cycles 3-18 followed by 20 mg/kg on day 1 of cycle 19 onward. Dex 8 mg IV + 28 mg PO is used during the weeks with Elo. Treatment will continue until disease progression, death, or withdrawal of consent. Pts will be followed up for response every 4 weeks until progressive disease and for survival every 16 weeks. The primary endpoint is PFS (90% power for a hazard ratio [experimental to control arm] of 0.74) and the secondary endpoints are ORR and overall survival. Exploratory endpoints are safety, time to response, duration of response, time to subsequent therapy, health-related quality of life, and pharmacokinetics and immunogenicity of Elo. Potential biomarkers will also be assessed. As of January 1, 2012, 13 pts were enrolled and 9 pts were treated. NCT01335399.
EVALUATING SMARTPHONE BASED PHOTOPLESYTHMOGRAPHY AS A SCREENING SOLUTION FOR ATRIAL FIBRILLATION: A DIGITAL TOOL TO DETECT AFIB?
Authors: Lars Grieten, Jo van der Auwera, Pieter Vandervoort, Maximo Rivero-Ayerza, Hugo Van Herendael, Philip De Vusser, Wim Anne, Peter Pollet, Karl Dujardin
Journal: Journal of the American College of Cardiology (2017)
Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI).
Authors: Sarah B. Goldberg, Geoffrey R. Oxnard, Subba Digumarthy, Alona Muzikansky, David Michael Jackman, Inga Tolin Lennes, Lecia V. Sequist
Journal: Journal of Clinical Oncology (2012)

7524 Background: EGFR-mutant NSCLC has an oncogene-addicted phenotype that confers sensitivity to EGFR TKIs. Prior data suggests EGFR addiction persists after development of TKI resistance, leading many clinicians to continue TKI along with chemotherapy (chemo); however, this strategy has not been formally evaluated. Methods: An institutional database was reviewed to identify patients (pts) with advanced NSCLC and acquired resistance to EGFR TKIs by Jackman criteria. Pts were included if they subsequently received chemo. Objective response rate (RR) to chemo/erlotinib or chemo alone was assessed by blinded radiographic review and compared by Fisher’s exact test and multivariable logistic regression. Progression-free survival (PFS) and overall survival (OS) from TKI failure (defined as chemo initiation date) were compared by log-rank test and multivariable Cox analysis. Results: 78 pts were eligible (34 chemo/erlotinib, 44 chemo alone). 70 pts (90%) had a documented EGFR mutation and were on TKI for a median of 15 months (range 4-51); in the 8 pts with unknown genotype the median duration on TKI was 11 months (range 5-16). Baseline characteristics were well balanced except more pts received erlotinib as initial TKI in the chemo/erlotinib group. RR was evaluable in 57 pts and was higher with chemo/erlotinib compared to chemo alone (41% vs 18%; OR 0.31, 95% CI 0.09, 1.04; p=0.08). RR adjusted for chemo regimen and time to TKI failure yielded OR 0.20 (95% CI 0.05, 0.78; p=0.02), favoring chemo/erlotinib. Median PFS was 4.4 months in the chemo/erlotinib group and 4.2 months in the chemo alone group (crude HR=0.84, 95% CI 0.52, 1.38; p=0.50; adjusted HR 0.79, 95% CI 0.48, 1.29; p=0.34). There was no significant difference in OS in the crude or adjusted analyses. Conclusions: This is the first study, to our knowledge, to show that continuation of an EGFR TKI with chemo compared to chemo alone significantly increases the RR in pts with advanced NSCLC and acquired TKI resistance, though we did not observe an impact on PFS or OS. Continued concurrent TKI may be a valuable strategy, particularly for pts with symptomatic progression, when a higher response rate may be beneficial. Further study is warranted.
Real world treatment patterns of gastrointestinal stromal tumor patients
Authors: J. A. Morgan, A. Guo, D. Williams, A. Guérin, D. Latremouille-Viau, M. Tsaneva, A. P. Yu, E. Wu, J. Signorovitch, G. D. Demetri
Journal: Journal of Clinical Oncology (2009)

e15602 Background: Imatinib is accepted as the standard first-line therapy to treat gastrointestinal stromal tumor (GIST) in patients with unresectable or metastatic disease. In the case of disease progression, physicians may consider increasing imatinib dose or switching to another second-line agent, such as sunitinib. The aim of this study was to analyze the real-world long term treatment patterns of GIST patients. Methods: Two large claims databases from 01/1999 to 03/2008 were combined (MarketScan and Ingenix Impact) to extract patients diagnosed with GIST who initiated on imatinib ≥400 mg/day. Patients were followed from the first observed imatinib prescription to the end of data availability. Patients who dose increased during the study period were defined as dose escalators, while patients who later switched to sunitinib with or without dose escalation were defined as switchers. Kaplan Meier analyses were used to estimate the rate of treatment changes over time including imatinib discontinuation, defined as a lack of imatinib supply for ≥60 days, and switching back to initial treatment. Results: Among the 1,508 GIST patients who initiated on imatinib, 253 patients had a dose increase and 153 patients switched to sunitinib during the study period. 20.1% patients on imatinib discontinued by the end of the first year, and 43.0% discontinued by the end of the third year. Among the 153 switchers, 61 patients had a dose escalation prior to the switch, of which 82.0% reached 800 mg before switching. Among all the switchers, 20.3% switched back to imatinib within 6 months. Conclusions: These claims-based findings on the duration of first-line imatinib therapy of GIST patients supports data on imatinib efficacy in treating GIST from formal clinical research studies. Most of GIST patients who initiated imatinib continued on this therapy without undergoing dose increase or switch to sunitinib. Among switchers, most did not dose escalate before switching and many eventually switched back to imatinib. It appears that physicians tend to not always follow clinical practice guidelines developed based on expert consensus, with respect to decision rules for dose escalation, or for the appropriate time to change kinase inhibitor therapy. [Table: see text]
ACUTE CORONARY SYNDROME: THE RISK TO BE YOUNG AND WOMEN
Authors: Beatrice Ricci, Edina Cenko, Zorana Vasiljevic, Marija Zdravkovic, Goran Stankovic, Davor Milicic, Aleksandar Lazarevic, Sasko Kedev, Olivia Manfrini, Akos Koller, Lina Badimon, Raffaele Bugiardini
Journal: Journal of the American College of Cardiology (2017)
The Role of Interleukin-15 on Natural Killer Cell Homeostasis and Activity in Patients with Acute Myeloid Leukemia
Authors: Mi roslaw J Szczepanski, Malgorzata Czystowska, Marta E Szajnik, Magis Mandapathil, Benedict Hilldorfer, Ann Welsh, Kenneth Foon, Theresa L Whiteside, Michael Boyiadzis
Journal: Blood (2008)
COMPARISON OF ADENOSINE FRACTIONAL FLOW RESERVE AND POST-CONTRAST INSTANTANEOUS WAVE-FREE RATIO FOR HEMODYNAMIC ASSESSMENT OF MODERATE CORONARY STENOSES
Authors: Samir B. Pancholy, Sukrut Nanavaty, Neha Pancholy, Maitri Pancholy, Kavit Pandya, John Coppola, Tak Kwan, Tejas Patel, Aman Patel, Hemant Tiwari
Journal: Journal of the American College of Cardiology (2017)
Role of IGF-1/IGFBP3 in non-small cell lung cancer sensitivity to therapy.
Authors: Inmaculada Ibañez de Cáceres, Esther Holgado, Olga Pernia, Javier De Castro, Ricardo Hitt, Esther Conde, Fernando López-Ríos, Maria Cortes Semperes, Rosario Perona, Cristobal Belda-Iniesta
Journal: Journal of Clinical Oncology (2013)

e19123 Background: Molecular mechanisms of drug-resistance remain still unclear; it is believed multifactorial, involving host factors, numerous molecular events as well as genetic and epigenetic changes. We were aimed to use massive expression assays before and after epigenetic treatment to explore predictors for platinum and radiation therapy in NSCLC. Methods: By using an expression microarray analysis, we looked for those genes reactivated in a set of two cisplatin (CDDP) resistant and sensitive NSCLC cell lines after epigenetic treatment. Gene expression, promoter methylation and CDDP-chemoresponse were further analyzed in three matched sets of sensitive/resistant cell lines, 23 human cancer cell lines and 36 NSCLC specimens. Then, to investigate the importance of methylation in radiosensitivity, we have developed radiation clonogenic cell survival assays with three paired Sensitive/CDDP-Resistant cell lines that present a different gene expression and promoter methylation profile. Finally, we have explored in vitro data into three cohorts of patients from different institutions that were treated with radio, chemoradiation or chemotherapy alone. Results: IGF-1/IGFBP3 axis was significantly associated with response to therapy and promoter methylation of IGFBP3 was critical to predict biological behavior. In this regard, hypermethylated and semimethylated cell lines presented a higher sensitivity to radiotherapy and cisplatin than cell lines completely unmethylated for IGFBP3 promoter. However, when resistance to cisplatin treatment was not mediated by IGFBP3 promoter methylation there were also not significant changes regarding sensitivity to radiotherapy treatment. Finally, in vitro data for IGF-1/IGFBP3 axis were confirmed in three cohorts of patients. Conclusions: IGF-1/IGFBP3 axis plays a central role in resistance to chemo- and radiation therapy in NSCLC patients.
The adjuvant role of low dose total body irradiation following chemoimmunotherapy in elderly high risk patients with diffuse large B-cell lymphoma (DLBCL)
Authors: A. Safwat, L. Specht, F. Hansen, M. Hansen, A. Boesen, J. Jurlander, F. D’Amore
Journal: Journal of Clinical Oncology (2006)

17523 Background: Results from the RICOVER-60 trial indicated a better outcome in elderly DLBCL patients (pts) by adding rituximab (R) to CHOP and shortening cycle intervals 14 days. We tested the addition of low dose total body irradiation (LTBI) to what proved to be the best performing arm of the RICOVER-60 trial (6xR-CHOP-14 + 2xR). Methods: A phase II trial including pts&gt;60 yrs with stage II-IV, CD20-positive DLBCL was started in 2003 and is still ongoing. Pts received 6x R-CHOP-14 and 2 x R alone followed by LTBI given as 2 courses of 4 daily fractions of 0,2 Gy separated by 2 weeks of rest. Subpopulations of blood lymphocytes, monoctytes and dendritic cells were identified by multi-color flowcytometry during treatment. Results: 24 patients finished their treatment and were found to be predominantly high risk. Median age was 68 years; 50% had ≥ 1 extranodal lesion; 71% had stage III or IV; 63% had B symptoms; 58% had ECOG score ≥ 1; 75% had elevated LDH and 58% had IPI of &gt;2. There were 3 toxic deaths (12.5%) due to sepsis occurring after 1 st , 3 rd and 5 th chemotherapy cycle, respectively. One patient got off study because of disease progression. 14 pts achieved a CR or CRu at the end of chemotherapy, while 6 were in PR. After LTBI, all 6 PR pts converted to CR. 3 pts relapsed within 7 months after achieving CR. All treatment failures occurred in patients with IPI 3&amp;4. 94%, 100% and 98% of the administered R-CHOP-14, Rituximab and LTBI cycles respectively were given in full dose and on time. CTC Gr 3–4 neutropenia occurred following 22 of 135 R-CHOP-14 cycles (16%). CTC Gr. 3–4 thrombocytopenia was seen in 4 pts following the last LTBI cycle (16%). Preliminary data from multi-color flowcytometry of the first seven pts, showed depletion of circulating B-cells, but in some pts, a relative increase in the frequency of circulating dendritic cells during chemotherapy, which was enhanced by LTBI. Conclusion: In high-risk elderly DLBCL pts, R-CHOP-14 is associated with potential fatal infections. LTBI adds relatively little extra toxicities in the form of thrombocytopenia and may have the potential of converting PR patients to CR. Testing lymphocytic subpopulations in peripheral blood may help elucidating the immunomodulatory mechanisms of LTBI. No significant financial relationships to disclose.
DIET AND ISCHEMIC BURDEN: A COMPARATIVE ANALYSIS OF A PLANT BASED REGIMEN VERSUS A MEDITERRANEAN REGIMEN IN PATIENTS WITH CORONARY ARTERY DISEASE
Authors: Rachid A. Elkoustaf, Mohamed Ismail, Columbus Batiste, Adina Mercer, Omar Aldaas, Darlene Newton
Journal: Journal of the American College of Cardiology (2017)
ARTERIAL STIFFNESS IS INCREASED AT INTERMEDIATE ALTITUDE: THE INTERVENCION TRIAL
Authors: Julio Chirinos Medina, Josefina Medina-Lezama, Offdan Narvaez, Karela Harrera, Mardelangel Zapata Ponze De Leon, Angely Janeth Rondon Rodriguez
Journal: Journal of the American College of Cardiology (2017)